Metals and elemental bioanalytical ICP-MS services for pharmacokinetics studies for metal based drugs or quantification of trace metals in biomarker studies
ICP-MS bioanalysis offers a quantitative and highly selective approach to elemental bioanalysis for pharmacokinetics studies for metal based drugs or for the quantification of trace metals in biomarker studies.
Metal containing drugs are currently being evaluated for a range of therapeutic applications including cancer, arthritis, diabetes and cardiovascular diseases. Examples include the use of platinum in cis-platin anti-cancer drugs, manganese-based metalloporphyrins and metal containing nanoparticles for either therapeutic or diagnostic applications. Determining these metals in preclinical and clinical samples is vital to the successful development of metal containing drugs, however, the analysis of very low detection limits, in biological matrices can present challenges.
Our experts use inductively coupled plasma with mass spectrometry detection (ICP-MS) for element specific quantitative bioanalytical evaluation of metals or other elements at very low levels, even down to parts-per-trillion (ppt) with few matrix interferences. We are adept at method development and validation and routinely conduct studies across a wide range of biological sample types to support both preclinical and clinical studies.
Alongside bioanalytical ICP-MS, Intertek offers a range of technologies in a Good Laboratory Practice (GLP) or Good Clinical Practice (GCP) compliant environment to determine levels of trace metals and other inorganic elements in clinical samples to support drug discovery, drug development and the safety assessment of implantable medical devices.
In addition, our UK facility has an on-site Class II Bio sample handling laboratory and a Human Tissue Licence, enabling the handling of clinical and diagnostic specimens.
Metals and inorganic bioanalysis services include
Metals and inorganic bioanalysis case studies
Need help or have a question?